Numerous studies have shown the efficacy of phage therapy in reducing foodborne pathogen carriage in food animals. Fewer studies have focused on host reactions, especially in terms of phage-mediated acute immune responses and effects on the gut microbiome. Here we administered E. coli O157:H7 phages in low (single dose of 10 5 PFU) or high (single dose of 10 7 PFU) quantities to mice. While there were time points at which cytokine levels in different treatment groups differed from one another, all cytokine levels remained within normal ranges for mice regardless of treatment. Similarly, the patterns of these differences were not dose related, indicating that phage treatment did not result in a strong acute immune response as measured here. In separate experiments, 3-week-old pigs received a diet containing an in-feed antibiotic or daily phage treatment. After two weeks, microbial DNA of ileal, cecal, and fecal contents was characterized using 16S rRNA sequencing. There were no statistical differences in performance among the different groups. Compared to control pigs (no antibiotic, no phage), antibiotic treatment significantly altered ileal microbiome composition (P < 0.05), with Bacilli being most affected (antibiotic treated: 22%; control: 76%; FDR D 0.0572). No significant differences were observed in cecal and fecal microbiome composition between antibiotic-treated and control pigs, and there were no differences in gut microbiome composition between phage treated and control pigs in any intestinal compartment. Significant abundance differences were observed at the OTU level, with OTUs belonging to genera such as Lactobacillus and Streptococcus being over-or underrepresented in either antibiotic or phage treated groups compared to control pigs. Determining whether these changes are deleterious to host, however, requires further study.
Introduction
Currently, there is substantial interest in the development of bacteriophage(phage)-based antibacterials for a variety of applications. Extensive studies have focused on measuring the efficacy of phage therapy in preventing or reducing undesired bacteria in food animals, food processing facilities, medical environments, and even humans. In agriculture, phage therapy has shown potential in reducing various foodborne pathogens, such as Salmonella in swine 1 and poultry, 2 Campylobacter in poultry, 3 and E. coli O157:H7 in ruminants. 4 Compared to many other antimicrobial strategies, especially antibiotic treatments, phage therapy has the unique advantage of being highly specific. It is common for phages to only affect specific bacterial serovars or even strains within a serovar. 5 As such, it is generally believed that, phages, even when applied in high concentrations via oral delivery, have limited collateral effect on untargeted bacteria and, as a result, are less likely to cause the microbial imbalances that are commonly observed as a side effects in antibiotic treatments. 6, 7 However, few studies, especially those using culture-independent techniques, have evaluated the impact of phages on the gut microbiome. 8 It is well established that the gut microbiome plays essential roles in animal growth and health. With the recent advances in 16S rRNA sequencing and metagenomic analysis, it is clear that an altered gut microbiome can significantly impact different metabolic and immunologic functions. 9, 10 Therefore, it is essential to more comprehensively evaluate the impact of phage therapy on the host gut microbiome. Additionally, the extent to which phages elicit host acute immune responses remains understudied as well. While animals are constantly exposed to phages in natural environment, much higher concentrations of phages are commonly used in phage therapy. Thus, it is equally important to evaluate whether phage challenge at high concentrations induces any adverse immune response to the animal host. In this study, we begin to address the hypothesis that phage treatment causes minimal host immune response and changes in untargeted microbial communities in the gut.
Materials and methods

Bacteriophages
An E. coli O157:H7 phage cocktail containing 3 unrelated phages (previously determined by genome sequencing) was used to measure the host immune response to phage treatment in a mouse model. The phages were originally isolated from wastewater and the cocktail was developed to as a possible preventative for E. coli associated diarrhea. The phages were previously shown to be effective in reducing E. coli O157:H7 contamination in ground beef and spinach. 11 Two of the 3 phages in the cocktail were previously sequenced. 12 Each phage was propagated individually overnight with the E. coli O157:H7 strain used in respective phage isolation and then the 3 phages were combined in equal volumes. The titer of the phage mixture was determined by plaque assay and then diluted to solutions of 10 8 PFU/mL (high phage group) and 10 6 PFU/mL (low phage group).
In a separate study, a 10-Salmonella phage cocktail was used to evaluate the impact of orally administrated phages on animal gut microbiome in a pig model. The ten phages were each isolated from geographically distinct wastewater treatment facilities and characterized by TEM and spectrum. This combination of phages, originally designed for broad spectrum, is the same cocktail of phages previously shown to be effective in preventing Salmonella infection in pigs. 1, 13 Similarly, each phage was propagated individually overnight with Salmonella typhimurium g4232 that was previously isolated from a diseased pig 1 and then all 10 phages were combined in equal volumes. The final concentration of the mixed phage cocktail was 1.07 £ 10 10 PFU/mL.
Mice immune responses to phage treatment
All animal experiments were approved by the Purdue University Animal Care and Use Committee (PACUC). Thirty-six BALB/c mice (18 males and 18 females; 5-week-old) were treated with 2 g/L of streptomycin (Sigma-Aldrich, S9137) in drinking water for 3 d. Mice were then divided into 3 groups (6 male and 6 female mice per group) and subjected to feed withdrawal for 24 h before phage treatment. Mice in the high phage group received 100 mL of E. coli O157:H7-phage cocktail at a concentration of 10 8 PFU/mL; mice in the low phage group received 100 mL of same phage cocktail at a concentration of 10 6 PFU/mL; and mice in the control group received 100 mL of 1x PBS. All treatments were delivered via oral gavage. At 6 h and 24 h post phage treatment, blood samples (submandibular) were collected from each mouse. Blood samples were centrifuged at 1,500 £ g to separate plasma from blood cells. Plasma samples were immediately used to measure the concentrations of 12 pro-inflammatory cytokines (IL1A, IL1B, IL2, IL4, IL6, IL10, IL12, IL17A, IFNg, TNFa, G-CSF, and GM-CSF) using a mouse inflammatory cytokines multi-analyte ELISArray kit (SABiosciences, MEM-004A).
Impact of phage therapy on the pig gut microbiome
Sixteen 3-week-old, Salmonella-free pigs were obtained from a high health commercial swine farm. Sows were not administered antibiotics post-farrowing, and pigs were not exposed to antibiotics in their nursery diet or creep feed before arrival. Upon arrival, pigs were housed in the same pen for one week as an adjustment period before they were assigned to one of the 3 treatments: control group (n D 6) where pigs received only a basal diet; phage group (n D 5) where pigs received a basal diet plus daily inoculation of 5 mL Salmonella-phage cocktail at a concentration of 1.07 £ 10 10 PFU/mL via oral gavage; and antibiotic group (n D 5) where pigs received a basal diet supplemented with an antibiotic premix ASP 250 ([Zoetis]; 100 g chlortetracycline, 100 g sulfamethazine, and 50 g penicillin per ton of feed). Pigs were housed individually with each pen equipped with separate feed and water systems (ad libitum). The three treatment groups were maintained at 3 separated regions of the animal house to prevent cross-contamination. All pigs were weighed weekly, and feed intake and health status were recorded daily. After two weeks of treatment, all pigs were euthanized and ileal contents, cecal contents, and fecal samples were collected.
Microbial DNA of each intestinal sample was extracted using a FastDNA TM spin kit for soil (MP Biologicals, Santa Ana, CA) following the manufacturer's protocol. For samples with high liquid content, liquid was removed by centrifugation at 10,000 £ g for 10 min before the suggested amount of sample was measured for DNA extraction. DNA samples were quantified using QuantiFluor Ò dsDNA system (Promega, Madison, WN), assessed for DNA integrity by gel electrophoresis, and stored at ¡20 C before use.
The construction of the 16S rRNA library was carried out in 2 steps. First, the V3 to V4 region of bacterial 16S rRNA gene was amplified using universal primers 338F (5 0 -ACTCCTACGGGAGGCAGC) and 806R (5 0 -GGACTACHVGGGTWTCTAAT) 14 containing Illumina adapter sequences with a cycling program of: 1) one cycle of 94 C for 5 min; 2) 25 cycles of 94 C for 30s, 60 C for 30 s and 72 C for 30 s; and 3) a final cycle of 72 C for 5 min. Each PCR included 25 mL KAPA HiFi HotStart ReadyMix, 2X (Kapa Biosystems, KK2601), 10 mM of each primer, 1 ng of template DNA, 0.5 mg/mL BSA (bovine serum albumin, Sigma-Aldrich, A9418), and sterile ddH 2 O to a final volume of 50 mL. The resulting amplicon was purified using the Agencourt AMPure XP PCR purification system (Beckman Coulter, A63880). Illumina 8 £ 12 TruSeq dual index sequencing primers (Illumina, FC-121-1003) were used to barcode individual samples in a second PCR using a cycling program of: 1) one cycle of 94 C for 3 min; 2) 8 cycles of 94 C for 30 s, 64 C for 30 s and 72 C for 30 s; and 3) a final cycle of 72 C for 5 min. Each PCR reaction included 25 mL KAPA HiFi HotStart ReadyMix, 2X, 10 mM of each primer, 5 mL of purified amplicon of first PCR, and sterile ddH 2 O to a final volume of 50 mL. The resulting amplicon was purified by gel electrophoresis and gel extraction using a QIAquick Gel Extraction kit (Qiagen, 28704). The final amplicon of each sample was quantified using the QuantiFluor Ò dsDNA System (Promega, E2670), mixed in equal amounts, and sequenced as a 16S rRNA library with the Illumina Miseq platform (2 £ 300 bp).
Sequence reads were sorted by barcode, quality filtered, and adapter-trimmed. The reads sequenced from 5 0 -end and 3 0 -end were merged based on the overlapping sequences, and a total of 37,891 to 547,061 merged reads were obtained for each sample. Due to the difference in total number of reads among samples, relative abundance was used for analysis. QIIME (Version 1.8.0) 15 was used to analyze and compare microbial community characteristics between samples. All merged reads underwent operational taxonomic unit (OTU) picking, taxonomic assignment, and phylogenetic tree construction using Green Genes (13_5) as a reference database. Weighted Uni-Frac distance matrices, accounting for differences in both phylogeny and relative taxon abundance, were generated and compared pairwise between treatments within each intestinal compartment using ANOSIM. A minimum of 25% of the total number of samples per comparison that had at least 1 read per OTU were used for downstream analyses. The relative taxon and OTU abundances were also compared pairwise between treatments within each intestinal compartment using the QIIME and Phyloseq software package 16 , respectively, and a FDR (false discovery rate) of 0.05 was used to determine statistical significance.
Statistical analysis
For mouse experiments, each cytokine level was standardized by dividing the measured value in treated mice by that of the positive control of corresponding cytokine on the same 96-well plates. The ratios were compared between control and low phage groups as well as between control and high phage groups at both 6 h and 24 h post treatment using a Student's t-test. For pig experiments, the growth performance data (average daily gain [ADG], weight gain [WG], daily feed intake [FI]) were compared among the 3 groups using a one-way ANOVA.
Results
Immune responses of mice to phage treatment
All mice remained healthy throughout the experiment. Among the 12 cytokines tested at 6 h and 24 h post treatment, most cytokines did not show significant differences between phage treated mice and controls. However, at 6 h post treatment, IL1A and IL2 concentrations in low phage treated mice were significantly higher (ratio of 0.2878 in low phage vs. 0.1653 in control for IL1A, P D 0.0379; and ratio of 0.2599 in low phage vs. 0.1865 in control for IL2, P D 0.0423) than those in control mice, while IL6 and IL12 concentrations in high phage treated mice were significantly lower (ratio of 0.3856 in high phage vs 0.4866 in control, P D 0.0379; and ratio of 0.1365 in high phage vs. 0.2355 in control, P D 0.0079) than those in control mice. At 24 h post treatment, IL1A, IL1B, and IL17A concentrations in high phage treated mice and GM-CSF concentration in low phage treated mice were significantly lower (ratio of 0.0383 in high phage vs. 0.0461 in control for IL1A, P D 0.0408; ratio of 0.0332 in high phage vs. 0.0479 in control for IL1B, P D 0.0004; ratio of 0.0241 in high phage vs. 0.0371 in control for IL17A, P D 0.0167; and ratio of 0.0761 in low phage vs. 0.0957 in control for GM-CSF, P D 0.0361) than those in control mice. All cytokine levels, however, were in the normal range for mice in all treatment groups at all sampling points.
Pig growth performance
All pigs remained healthy throughout the experiment. Pig growth performance, in terms of average daily feed intake (ADF), weekly weight gain (WG), and feed/gain ratio (F/G), was not different (P > 0.05) among pigs in control, phage, and antibiotic groups (Table 1) . However, pigs in the antibiotic group had a tendency to have higher WG at the second week of experiment (4.50 kg) compared to pigs in the control group (3.67 kg; P D 0.0642) and and pigs in the phage group (3.60 kg; P D 0.0546 ).
Gut microbiome analysis and comparison
Firmicutes and Proteobacteria were the most abundant phyla in the ileal microbiome of pigs across all treatments accounting for approximately 85% and 14% of reads, respectively. Firmicutes, Bacteriodetes, and Proteobacteria were the top 3 abundant phyla in the cecal content microbiome, accounting for 56%, 31%, and 11% of reads, respectively, and in the fecal microbiome as well, accounting for 58%, 26%, and 11% of reads, respectively (Fig. 1) .
Microbial communities were compared pairwise between treatments within each intestinal compartment. Weighted UniFrac distance matrices, which account for differences in both phylogeny and relative taxon abundance, were used as inputs for ANOSIM statistical analysis. The ileal microbiome of antibiotic treated pigs was statistically different from that of control pigs (P D 0.049; R D 0.37); however, differences were not observed in either the cecal (P D 0.123) or fecal (P D 0.348) microbiome between the 2 treatments. No differences were detected in the ileal (P D 0.12), cecal (P D 0.331) or fecal (P D 0.732) microbiome between phage treated pigs and controls. Relative taxon abundances at different taxonomic levels were evaluated by Student's t-tests. Most notably, Bacilli class trended toward being less abundant in the antibiotic-treated ileal microbiome compared to the control ileal microbiome (22% vs. 76%, Table 1 . Growth performance at week one (W1) and week 2 (W2) of antibiotic-treated, phage-treated, and control pigs, including average daily feed intake (ADF), weekly weight gain (WG), and feed/gain ratio (F/G). P-values represent comparisons among 3 treatments. (7), Oscillospira (1), and Ruminococcus (1) were significantly under-represented (FDR < 0.05) compared to the fecal samples of control pigs. Similarly, significant relative abundance differences were also observed in antibiotic treated group compared to control group at all 3 intestinal compartments. The extent to which the relative abundance of OTUs in phage treated or antibiotic treated groups were significantly different from control groups is described schematically in Figs. 2 and 3 .
Discussion
Phage therapy has shown great promise in preventing or reducing the carriage of foodborne pathogens in food animals. Here, we evaluated the impact of phages on host immune responses and the gut microbiome to better assess the safety of phage therapy and understand the outcome of applying high concentrations of phages to animals. In our experiments, we observed that orally administrated phages did elicit some cytokine responses in mice after 6 h and 24 h, but the cytokine levels were in the normal ranges of healthy mice. 17 Moreover, there were no clear patterns indicating that these minor differences were entirely treatment dependent. In all cases, differences were not dose-dependent and cytokine responses in phage treated mice were at times lower than in control mice. Taken together, these data indicate that phage treatment did not elicit an appreciable acute immune response. Similar results were reported by Miernikiewicz et al. 18 Our study also investigated the impact of phage treatment on pig gut microbiome. In general, the gut microbiome of pigs in our study, regardless of treatments, resembled the typical swine microbiome shown previously. 19, 20, 21 For example, the fecal microbiome of this study was dominated by bacteria belonging to Firmicutes, Batereroidetes, and Proteobacteria phyla, with Prevotella being the most abundant genus in the Bacteroidetes phylum. Meanwhile, the cecal microbiome had a similar composition as that of the fecal microbiome, while the ileal microbiome was dominated by Firmicutes and Proteobacteria.
Our results showed that phage treatment did not alter the overall composition of the gut microbiome at any tested gut compartment (ileum, cecum, colon). Similar results were also reported in a recent human study, where the oral administration of an E. coli phage cocktail to healthy adults at doses as high as 3 £ 10 9 PFU did not result in consistent changes in the fecal microbiome when compared to adults receiving a placebo. 22 The conservation of gut microbiome under phage challenge provided experimental evidence to the previous assumption that phages are highly host specific and have limited affect on untargeted gut bacteria. It is notable that both studies were conducted under conditions where animals or humans were not infected with phage-targeting bacteria. This could reflect a common phage application condition in practice, especially in agricultural uses, where phages are mostly designed for preventative interventions. On the other hand, a recent study evaluated the impact of phages on the mouse gut microbiome during infection where mice were colonized with an extraintestinal, pathogenic E. coli. Treatment with a phage cocktail effectively reduced the amount of challenge E. coli in the intestine without significantly affecting the surrounding microbiome at family levels as analyzed by 16S rRNA sequencing. 23 Unlike the extraintestinal E. coli in the aforementioned study, many foodborne pathogens are commensal bacteria in agriculture animals, possibly having an established niche in gut microbiome. In addition, for better application flexibility, phage cocktails designed for agriculture would likely have broad host spectrum. Therefore, there remain some unanswered questions regarding the impact of phages on the gut microbiome of infected animals under agriculture settings.
Compared to the control, no consistent relative abundance changes were observed in the phage treated microbiome at any tested intestinal compartments. Significant abundance increases or decreases in the phage treated microbiome compared to the control microbiome were only observed at OTU level. Deeper sequencing and improvement in 16S rRNA annotation in reference databases could enhance the OTU taxonomic assignment and therefore possibly provide a better idea of whether abundance changes of certain OTUs reflect abundance changes in certain bacterial genera or species. Likewise, further experiments are required to determine whether such changes are deleterious to animals.
Conversely, as was seen in related studies, 20,24,25 feeding the antibiotic growth promoter (ASP250) significantly altered the gut microbiome in pigs with the biggest impact in the ileum. The alteration in the antibiotic treated ileal microbiome was mainly driven by the relative abundance decrease in Bacilli class. Lactobacillus was one of the most affected genera in Bacilli class, with 21 OTUs assigned to Lactobacillus showing a significant abundance decrease in the antibiotic group. This was consistent with previous findings that feeding antibiotic growth promoters significantly affected Lactobacilli population. 26 However, both abundance increases and decreases have been reported in Lactobacillus species in response to different antibiotic treatments, 25, 26 which partly explains the fact that significant abundance changes were only observed at the OTU level and not the genus level. Additionally, previous studies showed significant abundance decreases in Streptococcus 27 and Turicibacter 25 in the ileal microbiome of antibiotic treated pigs. Significant abundance decreases in OTUs associated with each genus were observed in this study. It was noticed that one antibiotic treated ileal microbiome, compared to the other antibiotic treated ileal samples, deviated less from the control ileal microbiome. Interestingly, growth performance analysis indicated that the corresponding animal had significantly lower feed intake than the rest of animals in antibiotic group, which explains less antibiotic effect on ileal microbiome. No antibiotic-induced alteration was observed in either the cecum or feces. Besides the fact that the ileum was the first site exposed to antibiotics, the much less complex composition of ileal microbiome, compared to that of cecal and fecal microbiome, likely rendered the ileal microbiome more susceptible to alterations.
The antibiotic-induced alteration of the gut microbiome is considered one of the main factors contributing to antibiotic-associated growth promotion. One possible explanation is that feeding antibiotics reduces total bacterial load, and, consequently, reduces microbial nutrient utilization as well as the energy expended by the immune system in maintaining microbiome homeostasis. In our experiment, antibiotic treated pigs had numerically higher (P D 0.0834) weight gain than control and phage groups at second week. The lack of significant growth promotion could be due to a short experiment period and the fact that pigs in this study were housed in a very clean and bio-controlled environment, which has previously been shown to reduce the growth promoting effects of antibiotics. 28 Taken together, our studies evaluated the potential of oral administrated phages, at high concentrations, to elicit host acute immune responses and affect microbiome at different intestinal compartments. While phage treatment did elicit some cytokine responses, no adverse acute immune response was observed in mice. Meanwhile, compared to untreated pigs, no significant compositional changes or taxonomic abundance changes were observed after phage treatment; in contrast, antibiotic treatment resulted in significant composition changes in the ileal microbiome. While significant abundance changes were observed at some OTUs, further studies will be needed to determine whether such changes are deleterious to animal host. Additionally, metagenomic analysis on the gut microbial DNA samples may further reveal whether phage treatment is associated with changes in certain functional genes.
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